Semiparametric Bayes local additive models for longitudinal data

par Hua, Zhaowei, Zhu, Hongtu, Dunson, David B.
Publié dans Stat Biosci (2013)

Semiparametric Bayesian local functional models for diffusion tensor tract statistics

par Hua, Zhaowei, Dunson, David B., Gilmore, John H., Styner, Martin A., Zhu, Hongtu
Publié 2012

Model‐Based Meta‐Analysis for Multiple Myeloma: A Quantitative Drug‐Independent Framework for Efficient Decisions in Oncology Drug Development

par Teng, Zhaoyang, Gupta, Neeraj, Hua, Zhaowei, Liu, Guohui, Samnotra, Vivek, Venkatakrishnan, Karthik, Labotka, Richard
Publié dans Clin Transl Sci (2017)

Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial

par Zhou, Xiaofei, Friedlander, Sharon, Kupperman, Erik, Sedarati, Farhad, Kuroda, Shingo, Hua, Zhaowei, Yuan, Ying, Yamamoto, Yuka, Faller, Douglas V., Haikawa, Kazue, Nakai, Katsuhiko, Bowen, Sharon, Dai, Yi, Venkatakrishnan, Karthik
Publié dans Clin Transl Sci (2021)

Phase I Study of the Novel Investigational NEDD8-activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/refractory Multiple Myeloma or Lymphoma

par Shah, Jatin J., Jakubowiak, Andrzej J., O’Connor, Owen A., Orlowski, Robert Z., Harvey, R. Donald, Smith, Mitchell R., Lebovic, Daniel, Diefenbach, Catherine, Kelly, Kevin, Hua, Zhaowei, Berger, Allison J., Mulligan, George, Faessel, Helene, Tirrell, Stephen, Dezube, Bruce J., Lonial, Sagar
Publié dans Clin Cancer Res (2015)

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation s...

par Hou, Jian, Jin, Jie, Xu, Yan, Wu, Depei, Ke, Xiaoyan, Zhou, Daobin, Lu, Jin, Du, Xin, Chen, Xiequn, Li, Junmin, Liu, Jing, Gupta, Neeraj, Hanley, Michael J., Li, Hongmei, Hua, Zhaowei, Wang, Bingxia, Zhang, Xiaoquan, Wang, Hui, van de Velde, Helgi, Richardson, Paul G., Moreau, Philippe
Publié dans J Hematol Oncol (2017)

Brentuximab Vedotin with Chemotherapy for CD30-Positive Peripheral T-cell Lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

par Horwitz, Steven, O’Connor, Owen A, Pro, Barbara, Illidge, Tim, Fanale, Michelle, Advani, Ranjana, Bartlett, Nancy L, Christensen, Jacob Haaber, Morschhauser, Franck, Domingo-Domenech, Eva, Rossi, Giuseppe, Kim, Won Seog, Feldman, Tatyana, Lennard, Anne, Belada, David, Illès, Árpád, Tobinai, Kensei, Tsukasaki, Kunihiro, Yeh, Su-Peng, Shustov, Andrei, Hüttmann, Andreas, Savage, Kerry J, Yuen, Sam, Iyer, Swaminathan, Zinzani, Pier Luigi, Hua, Zhaowei, Little, Meredith, Rao, Shangbang, Woolery, Joseph, Manley, Thomas, Trümper, Lorenz
Publié dans Lancet (2018)